Carbon footprints by stage of chronic kidney disease: The case of Japan

被引:0
|
作者
Nagai, Kei [1 ,2 ]
Hata, Sho [3 ]
Itsubo, Norihiro [4 ]
Iseki, Kunitoshi [5 ]
Yamagata, Kunihiro [2 ]
Nansai, Keisuke [3 ]
机构
[1] Hitachi Gen Hosp, Dept Nephrol, 2-1-1 Jonan Cho, Hitachi, Ibaraki 3170077, Japan
[2] Univ Tsukuba, Fac Med, Dept Nephrol, 1-1-1 Ten Nodai, Tsukuba, Ibaraki 3058575, Japan
[3] Natl Inst Environm Studies, Mat Cycles Div, 16-2 Onogawa, Tsukuba, Ibaraki 3058506, Japan
[4] Tokyo City Univ, Fac Environm & Informat Studies, 3-3-1 Ushikubo Nishi,Tsuzuki Ku, Yokohama, Kanagawa 2248551, Japan
[5] Nakamura Clin, Clin Res Support Ctr, 4-2-1 Iso, Urasoe, Okinawa 9012132, Japan
来源
关键词
Chronic kidney disease; Carbon footprint; Dialysis therapy; GLOMERULAR-FILTRATION-RATE; RISK-FACTOR;
D O I
10.1016/j.joclim.2023.100294
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Introduction: The nexus between carbon footprints and chronic kidney disease (CKD) progression have not been clarified, so it has not been possible to examine the prevention of disease severity as a potential countermeasure for decarbonization. Material and methods: The study included 70,627 subjects aged 40 -74 years and diagnosed with CKD stage by specific health checkups in 2014 -2015. Greenhouse gas (GHG) emissions in Japan were formulated with the 2015 environmental input -output model. The carbon footprints by CKD stage were calculated with annual treatment cost according to renal function indicators, namely estimated glomerular filtration rate (eGFR) and proteinuria. Results: The annual carbon footprint per patient with induction of dialysis due to CKD was estimated to be 3.9 tCO 2 e, in contrast to 0.31 tCO 2 e in subjects without dialysis. Highlighting the relationship between the carbon footprint and the slope of eGFR as the CKD stage advances, the carbon footprint of care for patients with a stable eGFR in CKD stage G2 or better was 300 kgCO 2 e in males and 280 kgCO 2 e in females. Yet, in CKD stages G3a and G3b or worse, the carbon footprint for a rapid decrease in eGFR (30 % or greater per year) was 620 kgCO 2 e and 1440 kgCO 2 e in males and 430 kgCO 2 e and 1270 kgCO 2 e in females, respectively. Conclusion: Effective interventional treatments to prevent disease severity in CKD contribute to both the health of the patient and the mitigation of GHG emissions. (c) 2023 The Author(s). Published by Elsevier Masson SAS. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
引用
收藏
页数:6
相关论文
共 50 条
  • [1] A case of adult Dent disease in Japan with advanced chronic kidney disease
    Saida, Ken
    Kamijo, Yuji
    Matsuoka, Daisuke
    Noda, Shunsuke
    Hidaka, Yoshihiko
    Mori, Tetsuo
    Shimojo, Hisashi
    Ehara, Takashi
    Miura, Kenichiro
    Takita, Junko
    Sekine, Takashi
    Igarashi, Takashi
    Koike, Kenichi
    [J]. CEN CASE REPORTS, 2014, 3 (02): : 132 - 138
  • [2] A case of adult Dent disease in Japan with advanced chronic kidney disease
    Ken Saida
    Yuji Kamijo
    Daisuke Matsuoka
    Shunsuke Noda
    Yoshihiko Hidaka
    Tetsuo Mori
    Hisashi Shimojo
    Takashi Ehara
    Kenichiro Miura
    Junko Takita
    Takashi Sekine
    Takashi Igarashi
    Kenichi Koike
    [J]. CEN Case Reports, 2014, 3 (2) : 132 - 138
  • [3] Chronic kidney disease in Japan
    Iseki, Kunitoshi
    [J]. INTERNAL MEDICINE, 2008, 47 (08) : 681 - 689
  • [4] Prevalence and incidence of chronic kidney disease stage G5 in Japan
    Kunihiro Yamagata
    Takashi Yagisawa
    Shigeru Nakai
    Masaaki Nakayama
    Enyu Imai
    Motoshi Hattori
    Kunitoshi Iseki
    Takashi Akiba
    [J]. Clinical and Experimental Nephrology, 2015, 19 : 54 - 64
  • [5] Prevalence and incidence of chronic kidney disease stage G5 in Japan
    Yamagata, Kunihiro
    Yagisawa, Takashi
    Nakai, Shigeru
    Nakayama, Masaaki
    Imai, Enyu
    Hattori, Motoshi
    Iseki, Kunitoshi
    Akiba, Takashi
    [J]. CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2015, 19 (01) : 54 - 64
  • [6] Global case studies for chronic kidney disease/end-stage kidney disease care
    Yang, Chih-Wei
    Harris, David C. H.
    Luyckx, Valerie A.
    Nangaku, Masaomi
    Hou, Fan Fan
    Garcia, Guillermo Garcia
    Abu-Aisha, Hasan
    Niang, Abdou
    Sola, Laura
    Bunnag, Sakarn
    Eiam-Ong, Somchai
    Tungsanga, Kriang
    Richards, Marie
    Richards, Nick
    Goh, Bak Leong
    Dreyer, Gavin
    Evans, Rhys
    Mzingajira, Henry
    Twahir, Ahmed
    McCulloch, Mignon I.
    Ahn, Curie
    Osafo, Charlotte
    Hsu, Hsiang-Hao
    Barnieh, Lianne
    Donner, Jo-Ann
    Tonelli, Marcello
    [J]. KIDNEY INTERNATIONAL SUPPLEMENTS, 2020, 10 (01) : E24 - E48
  • [7] eGFR slope as a surrogate endpoint for clinical study in early stage of chronic kidney disease: from The Japan Chronic Kidney Disease Database
    Itano, Seiji
    Kanda, Eiichiro
    Nagasu, Hajime
    Nangaku, Masaomi
    Kashihara, Naoki
    [J]. CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2023, 27 (10) : 847 - 856
  • [8] eGFR slope as a surrogate endpoint for clinical study in early stage of chronic kidney disease: from The Japan Chronic Kidney Disease Database
    Seiji Itano
    Eiichiro Kanda
    Hajime Nagasu
    Masaomi Nangaku
    Naoki Kashihara
    [J]. Clinical and Experimental Nephrology, 2023, 27 : 847 - 856
  • [9] Cinacalcet in chronic kidney disease stage 4-case report
    Moeddel, M.
    [J]. SWISS MEDICAL WEEKLY, 2008, 138 (47-48) : 14S - 14S
  • [10] Stage IV Chronic Kidney Disease
    Hirsch, Sheldon
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (20): : 1942 - 1943